PRE-ANNOUNCEMENT: AFM-Telethon Calls for Proposals 2027


Announcement "open"
caduca en menys de 10 dies
I'm interested
Organization:
AFM Telethon
Category:
Altres
Scope:
International
Start:
Internal deadline:
Official deadline:
Amount:
Pending
Description:

a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }

AFM-Telethon will launch its 2027 funding programme supporting biomedical research on rare and neuromuscular diseases.

According to the pre-announcement, three schemes are expected to open in December 2026 (Call text and guidelines expected by late november):

  • Research Grants for projects addressing the understanding, prevention or treatment of rare and neuromuscular diseases.
  • Postdoctoral Fellowships supporting early-career researchers in relevant biomedical fields.
  • Trampoline Grants designed to help researchers generate preliminary data and strengthen future competitive applications.
  • Applications are expected to be submitted through a single-stage process.

Objective: To support innovative research and career development initiatives contributing to advances in rare and neuromuscular diseases.

Requirements

a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }

  • Research projects and researchers working in areas related to rare and neuromuscular diseases.
  • Open to applicants in France and abroad.
  • Specific eligibility conditions for each funding scheme are expected to be detailed in the official call documentation.
  • Consortium requirements: Not specified in the call documentation.
  • Career-stage requirements: Not specified in the call documentation, except that Postdoctoral Fellowships are intended for postdoctoral researchers.
Request

a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }

In case of interest, please click on 'm'interessa' and we will contact you.